4-anilinoquinoline-3-carbonitrile | 681215-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-anilinoquinoline-3-carbonitrile
• 英文别名: 4-phenylamino-3-quinolinecarbonitrile；SKI-606
• CAS: 681215-57-6
• 化学式: C₁₆H₁₁N₃
• 分子量: 245.283
• InChiKey: IYLIRRZCLARWKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氯-3-喹啉甲醛 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium tert-butylate 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 40.0h， 生成 4-anilinoquinoline-3-carbonitrile 、 1-phenyl-1H-pyrazolo[4,3-c]quinoline
  参考文献：
  名称：

  Palladium-Catalyzed Synthesis of 1H-Pyrazolo[4,3-c]quinolines and 4-Anilinoquinoline-3-carbonitriles from 4-Chloroquinoline-3-carbaldehydes

  摘要：

  Novel 1H-pyrazolo[4,3-c]quinolines and 4-anilinoquinoline-3-carbonitriles were prepared from readily accessible 4-chloroquinoline-3-carbaldehyde hydrazones by palladium-catalyzed intramolecular C-N bond formation and concurrent hydrazine N-N bond fission. These two classes of functionalized quinolines were chromatographically separable, and both are of biological interest. The ratio of the two products was found to be temperature-dependent; by changing the reaction temperature, either the pyrazoloquinoline or the anilinoquinolinecarbonitrile can become the dominant product.

  DOI：

  10.1055/s-0034-1381010

文献信息

• [EN] COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH<br/>[FR] COMPOSÉS MODULANT L'ACTIVITÉ DES RÉCEPTEURS EGFR ET MÉTHODES POUR TRAITER OU PRÉVENIR DES TROUBLES À L'AIDE DE CEUX-CI
  申请人：GATEKEEPER PHARMACEUTICALS INC

  公开号：WO2011140338A1

  公开（公告）日：2011-11-10

  Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith.

  提供了用于治疗或预防激酶介导的疾病的化合物和方法。
• [EN] INHIBITORS OF ACK1/TNK2 TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE ACK1/TNK2
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2015021149A1

  公开（公告）日：2015-02-12

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are ihibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specifc example, compound having Formula I through IV are disclosed.

  描述了癌症治疗和抗癌化合物。特别是，披露了Ack1酪氨酸激酶的抑制剂及其在癌症治疗中的应用。还披露了筛选新的Ack1酪氨酸激酶抑制剂的方法。在具体示例中，披露了具有I至IV式的化合物。
• Compounds, Compositions, and Methods for Cancer Therapy
  申请人：The Broad Institute, Inc.

  公开号：US20140024639A1

  公开（公告）日：2014-01-23

  Compounds including various oligomers of piperlongumine and/or piperlongumine analogues as well as certain piperlongumine analogues that exhibit improved toxicity to cancer cells are disclosed. Also provided are compositions that comprise the compounds, methods of making compositions comprising the compounds, methods of making the compounds, and the use of compounds in methods for treating cancer.

  本文披露了包括各种辣椒酸丁酯的寡聚体和/或辣椒酸丁酯类似物以及表现出对癌细胞有改进毒性的某些辣椒酸丁酯类似物的化合物。还提供了包括这些化合物的组合物、制备包括这些化合物的组合物的方法、制备这些化合物的方法，以及在治疗癌症方法中使用这些化合物的用途。
• [EN] SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS<br/>[FR] 3-CYANOQUINOLEINES SUBSTITUEES UTILISEES COMME INHIBITEURS DE MEK
  申请人：ASTRAZENECA AB

  公开号：WO2004005284A1

  公开（公告）日：2004-01-15

  The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹啉衍生物，其中Z1、m、R1、n、R3、Z2和R14中的每一个具有在描述中先前定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗侵袭或抗增殖剂的药物的用途中，用于包含和/或治疗实体肿瘤疾病。
• 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors
  申请人：Mayer Scott Christian

  公开号：US20090264427A1

  公开（公告）日：2009-10-22

  Imidazole-substituted 4-anilino-3-cyanoquinolines are described, which selectively inhibit IFGR kinase activity and are useful for treating disorders associated with IGFR kinases.

  描述了咪唑取代的4-苯胺基-3-氰基喹啉类化合物，其选择性抑制IGFR激酶活性，并可用于治疗与IGFR激酶相关的疾病。